ABG
CATX icon

Ally Bridge Group’s Perspective Therapeutics CATX Stock Holding History

Ally Bridge Group’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.54M Sell
743,958
-182,599
-20% -$690K 2.24% 18
2026
Q1 		$3.86M Buy
+926,557
New +$3.91M 3.12% 16
2024
Q4 		– Sell
-341,739
Closed -$4.56M – 32
2024
Q3 		$4.56M Sell
341,739
-54,503
-14% -$725K 2.44% 22
2024
Q2 		$3.95M Buy
+396,242
New +$5.73M 2.35% 21

Other funds holding CATX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Ally Bridge Group's CATX Position: Q2 2026 in Review

Ally Bridge Group reduced its Perspective Therapeutics (CATX) stake by 20% in Q2 2026, selling an estimated $690K and leaving 743,958 shares worth $2.54M. The position accounts for 2.24% of the portfolio, ranked #18.

Ally Bridge Group first reported a position in CATX in Q2 2024 and has held it in 4 quarters since. The position peaked at $4.56M in Q3 2024. 132 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

  • Ally Bridge Group held 743,958 shares of Perspective Therapeutics worth $2.54M as of Q2 2026.
  • Ally Bridge Group sold 182,599 Perspective Therapeutics shares in Q2 2026, an estimated $690K.
  • Perspective Therapeutics made up 2.24% of Ally Bridge Group's portfolio in Q2 2026, its #18 holding.
  • Ally Bridge Group first reported a position in Perspective Therapeutics in Q2 2024 and has held it in 4 quarters since.
  • Ally Bridge Group's Perspective Therapeutics position peaked at $4.56M in Q3 2024.
  • 132 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on Ally Bridge Group's 13F filing for Q2 2026, filed 14 Aug 2026.